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Available online 1 March 2017Plasma concentrations of pro-Atrial natriuretic peptide, proANP, are decreased in obesity anddiabetes. Decreased
proANP concentrations have also been noted after meal intake, and recently, a glucose-mediated regulation of
ANP gene expression was reported. Hence, we evaluated the effects of insulin, glucagon and glucose on plasma
proANP in a series of observational and experimental studies.
Six healthy men underwent seven days of bed rest. Before and after the bed rest, hyperinsulinemic euglycemic
clamps with serial plasma measurements of proANPwere performed. Moreover, plasma proANP was quantiﬁed
in 65 individuals with normal or impaired glucose regulation. Finally, the effects of infusion-induced
hyperglucagonemia were examined in ten healthy men.
Bed rest decreased insulin sensitivity and plasma proANP. The decrease in proANPwas not associated with insu-
lin sensitivity and the peptide concentrations remained constant during euglycemic hyperinsulinemia and hy-
perglycemic hyperglucagonemia. Impaired glucose regulation was not associated with decreased proANP
concentrations.
Bed rest per se induces a marked decrease in plasma proANP concentrations whereas insulin resistance and im-
paired glucose regulationwas not associatedwith lower proANP concentrations. Neither acute hyperinsulinemia
nor hyperglucagonemia seems to affect plasma proANP. Our ﬁndings thus suggest that decreased plasma proANP
concentrations occur late in the development of insulin resistance.Biochem
. This is©2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
ProANP
Insulin resistance
Metabolism
Hyperglycemia
Prediabetes1. Introduction
Atrial natriuretic peptide (ANP) is a member of the natriuretic pep-
tide family comprising also B-type and C-type natriuretic peptides. To-
gether with B-type natriuretic peptide, ANP is expressed mainly in the
cardiac atria and secreted to circulation upon cardiac strain; according-
ly, increased circulating concentrations are seen in heart failure settings
(Mukoyama et al., 1991). In the last decade, however, these cardiac hor-
mones have also been implicated in metabolic dysfunction, where de-
creased circulating concentrations have been reported in obesity,
insulin resistance, and diabetes (Jujić et al., 2016; Then et al., 2013;
Wang et al., 2007).istry, Rigshospitalet,
an open access article underRecently, a glucose-dependent transcriptional regulation of cardiac
ANP expression mediated by micro-ribonucleic acid-425 was reported
in stem cell-derived cardiomyocytes (Arora et al., 2016). Based on this
observation, hyperglycemia may be the mechanism underlying de-
creased plasma concentrations of ANP and its precursor, proANP, ob-
served in obesity and type 2 diabetes. In support of this, ANP secretion
decreases after a meal (Arora et al., 2016; Goetze, 2013), but whether
glucose per se, or in conjunction with post-prandial hormones (Jujić et
al., 2016), regulates the cardiac ANP expression, remains unclear. Im-
portantly, cardiomyocytes express receptors for both glucagon and in-
sulin and increased plasma concentrations of both hormones are well-
known features of obesity and type 2 diabetes (Brubaker and Drucker,
2002; Gammeltoft and Van Obberghen, 1986).
Hence, the objective of the present studywas to examine the cardiac
ANP response to insulin, glucagon and glucose. Speciﬁcally, we investi-
gated the effects of increased plasma concentrations of insulin and glu-
cagon in human infusion experiments,where plasmaglucosewas eitherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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centrations in middle-aged individuals with normal and impaired glu-
cose regulation. As physical inactivity is associated with not only
decreased muscle mass but also reduced glucose extraction in skeletal
muscle (Biensø et al., 2012), we also examined the ANP response to
short-term reduced insulin sensitivity by subjecting healthy humans
to a strict bed rest regimen. The mature ANP hormone is however con-
sidered unstable under most storage conditions. Hence, we quantiﬁed
plasma concentrations of the midregional part of N-terminal proANP,
a peptide that is co-secreted into the circulation in equimolar amounts
withmature ANP and thus considered a robustmarker of ANP secretion
(Davidson et al., 1995; Hall et al., 1995; Nelesen et al., 1995).
2. Materials and Methods
2.1. Research Design
The study included a series of three studies for which the design,
study populations and inclusion and exclusion criteria have been de-
scribed previously (Biensø et al., 2012; Færch et al., 2008; Guerra et
al., 2014; Hansen et al., 2015; Kiilerich et al., 2011; Ringholm et al.,
2011). The three studies were all performed according to the Declara-
tion of Helsinki and were approved by the regional ethical committee
(KA98155g, H-A-2008-0024 and H-1-2012-129). Prior to the experi-
ments, all participants gave written, informed consent to participate.
2.2. Bed Rest-induced Insulin Resistance
The study was performed at the Copenhagen University Hospital,
Rigshospitalet, Denmark, and the Department of Nutrition, Exercise
and Sports, University of Copenhagen, Denmark, and included six
healthy males with a mean (SD) age of 24.7 (4.4) years, weight of 68.9
(4.8) kg, height of 180.3 (4.8) cm, and body mass index (BMI) of 21.2
(4.4) kg/m2. As previously described (Biensø et al., 2012; Guerra et al.,
2014; Kiilerich et al., 2011; Ringholm et al., 2011), the participants
were subjected to seven days of bed rest including transportation by
wheel chair at all times and were served regular food and water ad
libitum. The day before the bed rest was commenced and on day 6 of
the bed rest, each subject underwent a standard oral glucose tolerance
test (OGTT). At 0, 30, 60, and 120 min after glucose intake, blood was
sampled and plasma concentrations of insulin and glucosewere quanti-
ﬁed. At baseline and at day 7, a 3 h hyperinsulinemic euglycemic clamp
(HIEC) was performed by infusing insulin (Actrapid; Novo Nordisk,
Bagsvaerd, Denmark) at a constant rate of 50 mU/m2/min for 3 h
(Biensø et al., 2012). Arterial blood glucose concentrations were mea-
sured every 5–10min throughout the procedure with a glucose analyz-
er (Radiometer ABL 725 series Acid-Base Analyser) and the glucose
infusion rate (GIR) was adjusted to maintain euglycemia. The average
GIR from 90 to 120 min from the start of the insulin infusion was used
as a measure of insulin sensitivity (theM-value). Moreover, the modi-
ﬁed Matsuda index was calculated from the OGTT as follows: 104/
(fasting plasma glucose (FPG) × fasting plasma insulin × mean plasma
glucose during the OGTT × mean plasma insulin during the OGTT)
(Matsuda and DeFronzo, 1999). Femoral venous blood samples were
collected into tubes containing EDTA before and after the bed rest peri-
od as well as 30 min prior to initiation of the clamp, at clamp initiation
(t= 0) and 30, 60, 120, 150, and 180min into the clamp. Blood samples
were centrifuged immediately and stored at−20 °C until analysis.
2.3. Prevalent Impaired Glucose Regulation
Participants were recruited from the Inter99 study which is a popula-
tion-based non-pharmacological intervention study to prevent ischemic
heart disease and type 2 diabetes (clinical trial reg. no. NCT00289237,
clinicaltrials.gov) (Jørgensen et al., 2003). After a 5-year follow-up exam-
ination, a sample of 120 participantswith either normal glucose tolerance(NGT; deﬁned as FPG b 6.1mmol/l and 2 h plasma glucose b 7.8mmol/l),
isolated impaired fasting glycemia (IFG; deﬁned as 6·1 mmol/-
l ≤ FGP b 7.0mmol/l but 2 h plasma glucose b 7.8mmol/l), or isolated im-
paired glucose tolerance (IGT; deﬁned as FPG b 6.1mmol/l but a 7.8 ≤ 2 h
plasma glucose b11.1 mmol/l) were subjected to another OGTT at the
StenoDiabetes Center, Gentofte, Denmark, and, if glucose tolerance status
was conﬁrmed, theywere invited to participate also in the present part of
the study (Færch et al., 2008). A total of 66 men and women (20 with
NGT, 18 with IFG, and 28 with IGT) agreed to participate and underwent
sampling of blood from the femoral vein followed by a 2-h HIEC. Details
have been provided elsewhere (Færch et al., 2008), but in brief, the
HIEC was started with a 9 min stepwise decline in insulin infusion
(Actrapid; Novo Nordisk, Bagsvaerd, Denmark) after which insulin was
infused at a constant rate of 40mU/m2/min for 2 h. Blood glucose concen-
trationsweremeasured every 5min throughout the clampwith a glucose
analyzer (One Touch Proﬁle glucose meter, Lifescan, Milpitas, CA, USA)
and the glucose infusion ratewas adjusted tomaintain blood glucose con-
centration of 5 mmol/l. TheM-value was calculated from the average GIR
during the last 30min of the clamp. Blood samples for proANP quantiﬁca-
tion were collected at baseline into tubes containing sodium ﬂuoride and
immediately placed on ice. After centrifugation, the samples were stored
at−80 °C until analysis.
2.4. Hormone Infusions
Ten healthy males were enlisted in the study which involved
four different infusion protocols each separated by at least a 14-day in-
terval: 1) 1-h intravenous glucagon infusion (GlucaGen, Novo Nordisk
Scandinavia, Copenhagen, Denmark; 6 ng/kg/min); 2) 2-h and 10 min
somatostatin-analogue infusion (Octreotide, Hospira Nordic AB, Stock-
holm, Sweden; 100 ng/kg/min) concurrent with 1-h glucagon infusion
(6 ng/kg/min); 3) 2-h and 10 min somatostatin-analogue infusion
(100 ng/kg/min), and 4) 1-h saline infusion (at the same rate as the
one used for the infusion of glucagon alone) (Hansen et al., 2015).
During the isolated somatostatin-analogue infusion, four additional
maleswere recruited to replace studyparticipantswhowerenot available
at the time. Themean (SD) age, weight, height, and BMI of the study sub-
jects in infusions 1, 2, and 4 was: 22.9 (0.4) years, 75.4 (2.1) kg, 183.8
(2.6) cm, and 22.3 (0.5) kg/m2, whereas study subjects in trial 3 had a
mean (SD) age, weight, height, and BMI of 23.0 (0.5) years, 72.9
(1.9) kg, 180.8 (1.7) cm, and 22.3 (0.5) kg/m2. Blood samples were col-
lected in tubes coated with EDTA at the onset (t = 0) and 30, 60, 90,
and 120 min into the infusions and placed on ice. The blood samples
were centrifuged and plasma was stored at−80 °C until analysis.
2.5. Plasma proANP Measurement
ProANP concentrations in plasma samplesweremeasured at theDe-
partment of Clinical Biochemistry, Rigshospitalet. ProANP was quanti-
ﬁed as proANP53–90 corresponding to the mid-regional part of proANP
by use of an automated assay on the KRYPTOR Plus system (Thermo-
Fisher Scientiﬁc, Hennigsdorf, Germany). According to the manufactur-
er, the detection limit of the assay is 2.1 pmol/l and the limit of quanti-
tation is 4.5 pmol/l. The intra-assay coefﬁcient of variation in the range
between 20 pmol/l and 1000 pmol/l is b2.5%.
2.6. Statistical Analyses
Statistical analyses were performed using SAS statistical software
version 9.4 (SAS institute, Cary, North Carolina, USA). When appropri-
ate, logarithmic transformations were applied to achieve normality
and homogeneity of the residuals. A p-value b 0.05 was considered sig-
niﬁcant. The present study includes a series of studies of previously pub-
lished cohorts. Hence, no sample size estimation was performed to
determine the sample size needed to detect a signiﬁcant difference in
Fig. 2. Plasma concentrations of pro-atrial natriuretic peptide before and after bed rest.
Peptide plasma concentrations were quantiﬁed before and after seven days of complete
bed rest in healthy young men (n = 6) and was compared by use of Wilcoxon signed
rank test (p = 0.03).
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spective cohorts were included.
In the bed rest study, the respective areas under the plasma insulin and
glucose curves during the OGTT, theM-value, the Matsuda index and the
plasma concentrations of proANP were compared before and after bed
rest by use of either paired t-tests or Wilcoxons signed rank tests. More-
over, Spearman's rank order correlations were used to assess the associa-
tions between plasma proANP and the areas under the insulin and
glucose curves, theM-value and theMatsuda index, respectively. In exten-
sion, the associations between the fold change inplasmaproANP (calculat-
ed as: (proANP concentration after bed rest - proANP concentration before
bedrest)/proANP concentration before bed rest) and the M-value and
Matsuda index after bed rest were assessed by use of Spearman's rank
order correlations. To assess the proANP response to clamp-induced
hyperinsulinemia before and after bed rest, plasmaproANP concentrations
weremodeled as linear functions of timeof blood sampling during the two
HIECs. To account for correlation among measurements of the same indi-
vidual, a shared randomeffect of each individualwas included in the linear
mixed model. Moreover, random individual intercepts and slope coefﬁ-
cients were included to allow for differences before and after bed rest.
For the population-based study of impaired glucose regulation, the
baseline characteristics, including plasma proANP concentrations,
among the three glucose tolerance groups were compared by use of
one-way ANOVAs with Tukey's post hoc tests or by use of the nonpara-
metric Kruskal-Wallis test followed by pairwise comparisons using the
Mann–Whitney U test. Gender distribution among the groups was tested
by use of a Chi square test. Least squares multiple linear regression anal-
yseswere used to assess the associations betweenproANP concentrations
as the dependent variable and theM-value and the presence or absence of
impaired glucose regulation (deﬁned by either IGT or IFG) as the explan-
atory variables. The two explanatory variables were entered separately
and the respective models were adjusted for age and sex. Finally,
Pearson's correlations were used to assess the associations between plas-
ma proANP and BMI, systolic and diastolic blood pressures, respectively.
For the hormone infusion study, repeated measures ANOVAs with
compound symmetry covariance structure were used to describe the
changes in plasma proANP concentrations during the four infusion ex-
periments. Time of blood sampling during the infusions was entered
as a repeated factor in the four respective statistical models. Post hoc
t-tests with Tukey–Kramer correction of the p-values were performed
if a signiﬁcant overall effect of timewas found in the respective models.Fig. 1. The Matsuda indices before and after bed rest. In six healthy young men, oral
glucose tolerance tests (OGTTs) were performed immediately before bed rest and at day
6 into the bed rest. The modiﬁed Matsuda index was calculated from fasting glucose and
insulin and mean glucose and insulin during the OGTTs. The modiﬁed Matsuda index
was compared before and at day 6 of bed rest by use of a Wilcoxon signed rank test
(p = 0.01).3. Results
3.1. Plasma proANP During Bed Rest-induced Insulin Resistance
After bed rest, insulin resistancewas conﬁrmed by increased plasma
insulin concentrations during oral glucose challenge (mean (SD) of the
areas under the insulin curves: 23,950.0 ± 8207.1 pmol/l versus
33,465.0 ± 9908.4 pmol/l; p = 0.03) whereas plasma glucose concen-
trations remained unaffected (mean of the areas under the glucose
curves 841.5 ± 101.1 mmol/l versus 882.5 ± 139.0 mmol/l; p = 0.6).
Accordingly, the Matsuda index was signiﬁcantly decreased by 45%
after bed rest (from 10.1 to 5.5 arbitrary units; p = 0.01; Fig. 1). Com-
pared to before bed rest, the median (IQR) M-value decreased after
bed rest (37.5 (32.1–46.7) μmol/min/kg body weight versus 27.0
(20.2–38.6)) μmol/min/kg body weight) but this difference did not
reach statistical signiﬁcance (p = 0.1). Plasma proANP concentrations
decreased from 40.1 (32.0–70.0) pmol/l before bed rest to 30.0 (26.3–
44.0) pmol/l after bed rest (p= 0.03, Fig. 2) but peptide concentrations
were not correlated to the M-value (p = 0.6) or the Matsuda index
(p= 0.8). Likewise when analyzed as fold change, plasma proANP con-
centrations were not correlated to either the M-value or the Matsuda
index after bed rest (both p = 0.9). The change in plasma proANP con-
centrations during the HIEC after bed rest was not statisticallyFig. 3. Plasma concentrations of proANP during acute hyperinsulinemia before and after
bed rest. Plasma concentrations of proANP were modeled as linear functions of time of
blood sampling during the two clamps. The slopes of the ﬁtted lines representing the
mean proANP concentrations during hyperinsulinemic euglycemic clamps before and
after bed rest, respectively, were not statistically signiﬁcantly different. Thus assuming
equal slopes, the estimated resultant slope of proANP concentrations over time during
hyperinsulinemia was not statistically signiﬁcantly different from 0 (n = 6). Data have
been log base e transformed and are shown as mean ± sd. ProANP = proatrial
natriuretic peptide.
Table 1
Descriptive data of the individuals with normal or impaired glucose tolerance.
NGT (n = 20) IFG (n = 18) IGT (n = 27) p-value
Gender (M/F) 11/9 16/2 15/12 0.04
Age (years) 49.8 ± 10.6 53.9 ± 7.6 53.9 ± 8.3 0.2
BMI (kg/m2) 25.6 ± 3.3 27.8 ± 3.6 28.1 ± 3.5⁎ 0.04
Diastolic BP (mmHg)a 76.6 ± 12.3 85.1 ± 11.4 82.5 ± 7.0 0.05
Systolic BP (mmHg)a 126.7 ± 17.5 136.9 ± 22.8 136.8 ± 17.3 0.2
Fasting plasma glucose (mmol/l) 5.5 ± 0.4 6.2 ± 0.3# 5.7 ± 0.4 b0.001
Fasting serum insulin (pmol/l) 28.5 (22.5–38.5) 39.5 (29.0–55.5) 39.0 (27.0–66.0) 0.2
M-value (×10−3 mmol/min/kg body weight) 49.3 ± 12.2 45.0 ± 20.3 35.4 ± 15.2⁎ 0.01
HOMA-IR 1.3 (1.0–2.0) 1.7 (1.4–2.5) 1.8 (1.2–2.7) 0.5
Pro-atrial natriuretic peptide (pmol/l) 46.3 ± 18.8 40.5 ± 20.4 47.7 ± 22.4 0.5
Overall group-wise differences were analyzed by use of one-way ANOVA or Kruskal-Wallis tests followed by pairwise comparison of groups. NGT, normal glucose tolerance, IFG, isolated
impaired fasting glucose, IGT, isolated impaired glucose tolerance, HOMA-IR, Homeostatic model assessment of insulin resistance calculated as fasting insulin (mIU/L) × fasting glucose
(mmol/L) divided by 22.5.
Data are presented as mean ± SD or, in case of non-normal distribution, median and interquartile ranges.
a Due to missing observations for systolic and diastolic blood pressure (BP) measurements, the sample size is reduced to n = 19, n = 17 and n = 21 for NGT, IFG and IGT groups,
respectively.
⁎ p b 0.05 vs. the NGT group.
# p b 0.05 vs. the NGT and the IGT groups.
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tions during the HIEC before bed rest (p = 0.9). Hence assuming
equal change in proANP, no effect of hyperinsulinemia was found
(p = 0.4). Nonetheless, mean plasma proANP in the HIEC after bed
rest was signiﬁcantly decreased compared to mean plasma proANP in
the HIEC before bed rest (p= 0.002; Fig. 3), corroborating the net effect
of bed rest.
3.2. Plasma proANP in Impaired Glucose Regulation
The circulating proANP concentration was not quantiﬁed in one in-
dividual with IGT due to inadequate amount of plasma. A total of 65 in-
dividuals were thus included in the study (Table 1). The distribution of
gender differed among groups (p = 0.04) and individuals with IGT
displayed higher BMI and lower insulin sensitivity than individuals
with NGT (p= 0.04 and 0.01, respectively). Plasma proANP concentra-
tions did not differ among the three groups (p= 0.5, Table 1). Likewise,
proANP concentrations were not associated with either presence of im-
paired glucose tolerance (p = 0.3) or the M-value (p = 0.7). Plasma
proANPwas not correlated to either BMI (p=0.7) or systolic or diastol-
ic blood pressures (p = 0.8 and p = 0.9, respectively).
3.3. Plasma proANP During Hormonal Infusions
Overall, infusion of glucagon alone signiﬁcantly affected plasma
proANP concentrations (p=0.008) and on post hoc testing, the peptide
concentrations decreased from 48.2± 16.5 pmol/l at baseline to 44.1±
13.1 pmol/l 90 min into the infusion (p = 0.03). Neither infusions of
glucagon in the presence of a somatostatin-analogue nor infusions of a
somatostatin-analogue alone affected the circulating proANP concen-
trations (p = 0.07 and p = 0.1, respectively). Saline infusions were
per se associated with an overall change in circulating proANP (p =
0.004) comprising a decrease in peptide concentrations at 60, 90, and
120 min into the infusion compared to onset of the infusion (p =
0.02; p = 0.004 and p = 0.02, respectively) (Fig. 4).
4. Discussion
In the present study, we found that seven days of bed rest induced a
marked decrease in proANP concentrations in plasma from healthy
young men. Moreover, bed rest was associated with decreased insulin
sensitivity, but a signiﬁcant association between the magnitude of the
induced insulin resistance and plasma proANP concentrations was not
found. Likewise, presence of impaired glucose regulation among mid-
dle-aged men and womenwas not associated with low plasma proANPconcentrations. Finally, neither hyperinsulinemia nor isolated
hyperglucagonemia acutely affected proANP concentrations in healthy
lean individuals.
The effects of (supine and head-down) bed rest on ANP concentra-
tions have been examined before. In the circulation, however, ANP has
a very short half-life and may mainly represent hemodynamic changes
including altered renal elimination. Therefore, the overall decrease in
ANP concentrations noted in these early studies was ascribed the car-
diovascular changes observed during bed rest (Gauquelin et al., 1996,
1995; Maillet et al., 1994). Bed rest, however, also has profound effects
on themetabolic homeostasis and the induction of insulin resistance, in-
cluding decreased activity of key proteins involved in glucose transport,
has been well described (Biensø et al., 2012; Stuart et al., 1988). Hence,
in the present study we investigated the bed rest-induced proANP re-
sponse, as proANP is amuchmore stable marker of cardiac ANP expres-
sion and without the same elimination mechanism in circulation.
Decreased insulin sensitivity including glucose-mediated
hyperinsulinemia was successfully induced and plasma proANP was
signiﬁcantly decreased after bed rest. Nonetheless, we were not able
to detect a signiﬁcant association between indices of insulin sensitivity
and plasma proANP or between the decrease in proANP and themagni-
tude of the induced insulin resistance in the population in question. The
bed rest-induced decrease in plasma proANP concentrations may thus
reﬂect other physiological processes than decreased insulin sensitivity
such as plasma volume reduction and cardiac atrophy due to reduced
myocardial load in the supine position (Perhonen et al., 2001).
To further elucidate the link between circulatingmarkers of ANP ex-
pression and insulin resistance, we quantiﬁed circulating proANP con-
centrations in middle-aged men and women with prevalent impaired
glucose regulation. We found that individuals with impaired glucose
tolerance had similar proANP levels as individuals with normal glucose
tolerance. In line with this, proANP concentrations did not differ be-
tween individuals with isolated impaired fasting glycemia and individ-
uals with isolated impaired glucose tolerance, and the concentrations
were not associatedwith insulin sensitivity. Theseﬁndings contrast pre-
vious cross-sectional population-based studies reporting lower circulat-
ing proANP concentrations in obesity, insulin resistance, and diabetes
(Then et al., 2013; Wang et al., 2007). Head-on comparisons with
these studies are hampered by the broad clinical spectrum of the syn-
dromes of insulin resistance ranging from obesity over type 2 diabetes
to extreme insulin resistance. In the present study, the deteriorated in-
sulin sensitivity induced by bed rest was characterized mainly by an in-
creased insulin response to an oral glucose challenge, whereas the
prevalent cases of insulin resistance represented normal to prediabetic
states of hyperglycemia and not type 2 diabetes (Færch et al., 2008).
Fig. 4. Effect of hyperglucagonemia on plasma concentrations of pro-atrial natriuretic peptide. In ten healthymen, the infusion of glucagon alone resulted in signiﬁcantly decreased plasma
proANP concentrations at 90min into the infusion compared to the onset (t= 0min) (A). In the presence of a somatostatin-analogue, however, infusions of glucagon did not alter plasma
proANP concentrations (B). Likewise, plasma proANP was unaltered during the infusion of a somatostatin-analogue alone (C). Saline infusions per se altered proANP concentrations
overall, comprising a decrease at 60, 90, and 120 min into the infusion compared to the onset of infusions (D). Data are shown as mean ± sd and was analyzed by use of repeated
measures ANOVA.
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were non-obese and with early low-grade insulin resistance, whereas
the previous population-based studies included signiﬁcantly more indi-
viduals and awider range of insulin resistance including overt type 2 di-
abetes. Taken together, it is therefore conceivable that decreased cardiac
ANP secretionmay represent a later event in disease progression,where
the early stages are not affected or perhaps compensated.
In the present study we also investigated plasma pro-ANP in acute
hyperinsulinemic settings but found that peptide concentrations were
unaffected by acute euglycemic hyperinsulinemia before and after bed
rest. Early studies investigated circulating concentrations of the mature
ANP hormone iunder hyperinsulinemic conditions but reached diver-
gent conclusions in individuals with normal glucose regulation (Clark
et al., 1993; Gans et al., 1996; Miller et al., 1993; Nannipieri et al.,
2002; Ohno et al., 2001; Trevisan et al., 1990) as well as in individuals
with type 2 diabetes Several factors may account for these discordant
ﬁndings, including different methodology and demographics of the in-
cluded study subjects, the lack of stability of mature ANP and the high
variability among assays quantifying ANP (Clerico et al., 2000). One pre-
vious study however quantiﬁed circulating proANP concentrations in
obese men and reported decreased concentrations of proANP after
euglycemic and hyperglycemic hyperinsulinemia, respectively
(Pivovarova et al., 2012). In contrast to this latter study, the population
investigated in the present study were young individuals with a BMI in
the low range of what is classiﬁed as normal weight. Differential natri-
uretic peptide clearance in obese and normal weight adults mediated
by an increased expression of NPRC, the gene encoding the natriuretic
peptide clearance receptor, has been indicated in previous studies
(Kovacova et al., 2016) and it is thus possible that also a differential se-
cretion of ANP exists between obese individuals and their normalweight counterparts. Even though the lack of a statistically signiﬁcant
effect does not equal the lack of true biological effect (particularly in
small populations such as ours), the changes in plasma proANP concen-
trations during the two HIECs were extremely small, thus supporting a
lack of effect of euglycemic hyperinsulinemia in the present population.
Our ﬁndings thus discourage the notion of ANP expression being regu-
lated directly or indirectly by plasma insulin in lean individuals but
this notion cannot necessarily be extended to an overweight and
obese population.
Apart from hyperinsulinemia, early stages of insulin resistance
are characterized by hyperglycemia as well as a defective suppres-
sion of glucagon secretion (Ahrén, 2009; Færch et al., 2016). There-
fore, we also investigated the proANP response to manipulations of
insulin, glucose, and glucagon in healthy young men. During isolated
hyperglucagonemia, i.e., increased plasma glucagon in the presence
of somatostatin-induced suppression of other hormones, proANP
concentrations remained unaffected, indicating that glucagon per
se is not involved in the regulation of cardiac ANP secretion. Surpris-
ingly, a modest decrease in plasma proANP was observed during in-
fusions of glucagon and saline per se. Seeing that the infusion of
glucagon alone was accompanied by a glucagon-induced release of
glucose (peaking at 6·8 mmol/l), which in turn stimulated pro-
nounced insulin release (Hansen et al., 2015), it cannot be rejected
that the combination of hyperglucagonemia and hyperinsulinemia
may downregulate cardiac ANP expression. Of note, however, the
magnitude of the observed decrease in plasma proANP was very
modest and may thus not be biologically signiﬁcant. Therefore, fur-
ther studies are needed before this notion is convincingly supported.
Although our experimental setup was not aimed at investigating the
effects of blood glucose, our data do not support the notion of glucose
93N.E. Zois et al. / EBioMedicine 17 (2017) 88–94per se being involved in the regulation of ANP secretion, as has re-
cently been suggested (Arora et al., 2016). First, marked hyperglyce-
mia (peaking at 12.5 mmol/l), as was observed in isolated
hyperglucagonemia due to blockage of endogenous insulin release,
did not affect plasma proANP, whereas proANP concentrations de-
creased during the infusions of saline and glucagon where
normoglycemic conditions were present. Second, the middle-aged
individuals with a prediabetic state of hyperglycemia, represented
by either increased blood glucose in the fasting state or, after an
oral glucose challenge, did not exhibit signiﬁcantly decreased plas-
ma proANP.
Of note, the lack of detectably decreased cardiac ANP expression in
low-grade insulin resistance, acute hyperinsulinemia and acute
hyperglucagonemia found in the present study does not necessarily
equal preserved ANP signaling to target organs. Several lines of evidence
have pointed at defective ANP signaling being an early event in the pro-
gression of metabolic dysfunction (Coué et al., 2015; Kovacova et al.,
2016; Pivovarova et al., 2012). Speciﬁcally, the ratio of the gene expres-
sion levels of the natriuretic peptide receptors type A and C is decreased
already at early stages of a dysregulated glucose metabolism (Kovacova
et al., 2016). As the natriuretic peptide receptors type A is considered
primary responsible for ANP signaling whereas the natriuretic peptide
receptors type C is mainly a clearance receptor, this change conveys a
reduced biological activity of ANP.We did however not quantify the ex-
pression levels of the genes encoding the peripheral receptors in the
present study and decreased ANP bioavailability may thus have been
present.
Moreover, we do acknowledge the fact that proANPmaynot fully re-
port on acute changes due to the prolonged elimination phase. Howev-
er, as plasma half-life of approximately 60 min has been reported for
proANP (Murthy et al., 1988) we do expect signiﬁcant changes in
proANP secretion to be reﬂected during infusion experiments of 2–
3 h' duration as were performed in the present study.
In conclusion, short term bed rest induced a marked decrease in
plasma proANP concentrations. According to our ﬁndings, this decrease
reﬂected other aspects of bed rest than the induced insulin resistance. In
line with this, individuals with impaired glucose regulation had similar
plasma proANP levels as age-matched normoglycemic controls. Finally,
neither acute euglycemic hyperinsulinemia nor hyperglycemic
hyperglucagonemia per se were associated with changes in circulating
proANP in lean individuals. Altogether, our ﬁndings suggest that cardiac
proANP – today used as a clinical marker of cardiac dysfunction – is not
affected by acute hyperinsulinemia, hyperglucagonemia, or hyperglyce-
mia in non-diabetic lean individuals.Funding
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